Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of HMPL-506 in Patients With Hematological Malignancies

Next Previous
Trial Profile

A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of HMPL-506 in Patients With Hematological Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HMPL 506 (Primary)
  • Indications Acute myeloid leukaemia; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors HUTCHMED

Most Recent Events

  • 07 Mar 2025 Number of treatment arms increased from 5 to 13 by the addition of new Experimental arms for different dosages as follows: 25 mg BID, 50mg BID, 75 mg BID, 150mg QD, 100mg BID, 150mg BID, 200mg BID and Other dose determined by SRC.
  • 07 Mar 2025 Planned number of patients changed from 98 to 132.
  • 31 May 2024 Status changed from not yet recruiting to recruiting, according to a HUTCHMED media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top